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Abstract 22 
Background 23 
Many studies have found an increased risk of pulmonary tuberculosis (PTB) amongst those 24 
with diabetes mellitus (DM). However, evidence on whether the association is bi-directional 25 
remains sparse. This study investigates DM rates amongst those with and without prior 26 
tuberculosis (TB) disease as well as the reverse. 27 
Methods 28 
Data on a UK general practice population, between 2003 and 2009, were obtained from The 29 
Health Improvement Network database. A series of retrospective cohort studies were 30 
completed. Individuals were successively classified as ‘exposed’ or ‘unexposed’ to TB, PTB, 31 
extra-pulmonary TB (EPTB), or DM . Multivariate negative binomial regression was used to 32 
calculate incidence rate ratios (IRR) amongst each exposure group for outcomes of interest 33 
(TB, PTB, EPTB, or DM in turn) adjusting for plausible confounding variables (age, sex, region, 34 
Townsend quintile and smoking status). Potential confounding due to ethnicity was adjusted 35 
for using McNamee’s external method. 36 
Results 37 
DM risk was substantially raised amongst individuals with a history of TB disease (IRR 5.65 38 
(95% CI 5.19-6.16)), PTB (IRR 5.74 (95% CI 5.08-6.50)), and EPTB (IRR 4.66 (95% CI 3.94-5.51)) 39 
compared to those without; results were attenuated after external adjustment for ethnicity 40 
(IRR 2.33 (95%CI 2.14-2.53)). TB risk was raised modestly amongst individuals with DM (IRR 41 
1.50 (95%CI 1.27-1.76)), and was attenuated slightly after adjustment for ethnicity (IRR 1.26 42 
(95%CI 1.07-1.48)). 43 
Conclusion 44 
DM risk was raised among those with previous TB disease; this finding has implications for 45 
follow-up and screening of TB patients, who may be at high risk of developing DM or related 46 
complications.  47 
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Introduction 48 
Despite consolidated control efforts, the TB burden remains high in many places in the world. 49 
In 2016 an estimated 10.4 million people were diagnosed with TB and 1.7 million died from 50 
the disease(1). Global diabetes (DM) prevalence has been steadily increasing in recent 51 
decades. Estimates produced by the International Diabetes Federation suggest that by 2045 52 
a 55% increase in DM burden will occur worldwide, with the greatest increases projected to 53 
occur in regions where TB remains endemic(2). 54 
An association between TB and DM has long been known although its importance has been 55 
under recognised(3-5). Two systematic reviews published nearly 10 years ago revitalised 56 
awareness of this link showing that DM increases TB risk by three-fold(3, 6). This association 57 
has since been further confirmed by more contemporaneous studies conducted in both TB 58 
endemic regions and developed countries(7-11) but not always by those completed in low TB 59 
burden countries(12). To date, most studies of the association have been cross-sectional or 60 
cohort in design with DM as the “exposure” and TB as the “outcome”.  61 
A bi-directional association between TB and DM is biologically plausible(13, 14), but there is 62 
limited evidence to support or refute whether people with a history of TB are at increased 63 
risk of developing DM(8). It remains important to identify epidemiologically whether the 64 
increased risks of TB seen among DM patients are truly bidirectional, and clinically whether 65 
patients with TB might benefit from future screening for DM. TB patients often develop 66 
hyperglycaemia during TB treatment, though this may be transient(10). Whether or not future 67 
risk of DM is raised for those with “transient hyperglycaemia” is unknown, though logical(15).  68 
It is generally thought that DM increases the risk of pulmonary TB (PTB) rather than extra-69 
pulmonary TB (EPTB)(3, 16). However, there is limited available evidence at present on 70 
associations between different TB manifestations (PTB, EPTB) and DM subtypes (T1DM, 71 
T2DM)(8). Most studies are underpowered to explore these potential associations as EPTB 72 
accounts for less than 20% of global TB and only around 10% of DM is T1DM, thus it is difficult 73 
to confirm cases with diagnosis of both in many low and middle income countries (LMIC) 74 
where TB burden is high. The Health Improvement Network (THIN) – a very large, widely 75 
validated and used administrative dataset of UK primary care health data (17)—was used in 76 
this study to facilitate the investigation in this research area.    77 
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Methods 78 
Ethical Approval 79 
Data collection for THIN was approved by the South East Multicentre Research Ethics Committee 80 
(MREC) in 2003. This individual study did not require separate ethical approval as only anonymised 81 
THIN data is used, however it was reviewed by THIN independent Scientific Review Committee. 82 
Data source, definition of exposures and outcomes 83 
Data were obtained from the THIN database which contains the electronic medical records 84 
of 6.9 million patients collated over 385 GP practices in the UK, covering approximately 5.7% 85 
of the total population in a representative manner(17). The study population comprised all 86 
individuals in THIN database with active records between 2003 and 2009 that met THIN 87 
minimum data acceptability standards at both practice and patient level with no gaps in 88 
practice records. All patients were actively registered either currently or historically. 89 
Each exposure cohort (DM, TB, PTB, and EPTB) was constructed in the same way, dynamically 90 
with individuals selected in from the date of their first record on file for said exposure 91 
between the 01/01/2003 and 31/12/2009. Each individual’s files were then searched for a 92 
subsequent record of an outcome of interest. Individuals left each cohort either on the study 93 
end date (31/12/2009), on their date of death, or GP de-registration. Unexposed cohorts were 94 
constructed from aggregated denominator data provided by CSD-Medical Research UK, the 95 
gatekeepers to THIN at the time this study was completed. Records from the THIN database 96 
undergo in-house data quality checks and only data flagged as passing these checks were 97 
used. Further data quality checks were completed to ensure no implausible values existed for 98 
any variable of interest and that date of birth, registration and death occurred sequentially. 99 
Using a combination of hierarchical Read codes, individuals were categorised as having: TB, 100 
PTB, EPTB, or DM. TB diagnosis codes refer to TB disease, and do not include latent TB 101 
infection. When there was uncertainty on how a Read Code should be categorised, a third 102 
opinion was sought by a chest physician as appropriate (see Appendix 1—6). The majority of, 103 
but not all, individuals within the TB cohort are subcategorised in to the PTB or EPTB cohort. 104 
Data on key confounders including age, sex, socioeconomic status ((SES) based on Townsend 105 
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Quintile, a score of material deprivation linked to each individuals postcode), and smoking 106 
status were obtained from the appropriate THIN data fields. 107 
Statistical Methods 108 
Univariate analyses were conducted to identify which variables were associated with both TB 109 
and DM. Results were calculated as IRRs with 95% CI and an alpha value of p<0.05 was used 110 
as standard. Following this, multivariate analyses using a negative binomial model were 111 
completed to explore whether DM was associated with TB, PTB or EPTB, and the converse 112 
accounting for plausible confounding. Ethnicity could be an important confounder of the 113 
explored relationships, in particular where TB is the exposure and DM the outcome. 114 
Unfortunately, ethnicity has been poorly recorded in UK primary care datasets. Therefore, we 115 
have externally adjusted for ethnicity as a confounder of the bidirectional association 116 
between TB and DM using a method outlined by McNamee(18); the detailed method can be 117 
found in Appendix 7. Individuals with missing data for main variables of interest were 118 
excluded from datasets since the total number with missing data was small (<1%).  119 
 120 
  121 
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Results 122 
Within the THIN dataset there were 224,508 individuals in the DM cohort, 5,470 in the TB 123 
cohort, 1,589 in the PTB cohort; and 1,006 in the EPTB cohort. The mean age of entry into the 124 
DM cohort was 60 years, TB cohort 48 years, PTB cohort 53 years, and EPTB cohort 47 years 125 
respectively. Average follow up for each cohort was 4.1 years, 3.7 years, 3.7 years, and 4 years 126 
respectively. Sex, age, SES, and smoking distribution for the DM and TB cohorts are given in 127 
Table 1.  128 
The rate of DM was significantly increased amongst those who had previously had TB (all sub-129 
types) (IRR 5.65 (95% CI 5.19-6.16)). This was also the case for both PTB (IRR 5.74 (95% CI 130 
5.08-6.50)) and EPTB (IRR 4.66 (95% CI 3.94-5.51)), compared with those who had not had TB 131 
(see Table 2). We estimated that IRRs may be inflated by about 2 to 2.5 fold due to residual 132 
confounding by ethnicity (Appendix 7), suggesting that after this external adjustment for 133 
ethnicity, the true IRR could be attenuated from 5.65 to around 2.33 (95%CI 2.14-2.53) up to 134 
2.90 (95%CI 2.66-3.16).  135 
The IRR of TB was significantly increased amongst individuals with DM (IRR 1.50 (95%CI 1.27-136 
1.76)) compared to those without (see Table 2). The rate of PTB amongst individuals with DM 137 
(IRR 1.24 (95%CI 0.93-1.64)) and the rate of EPTB amongst those with DM (IRR 1.43 (95% CI 138 
0.99-2.07)) when compared to those without DM was not significantly raised. External 139 
adjustment for ethnicity attenuated the estimates of DM amongst those with TB by 1.2 to 1.4 140 
fold, see Appendix 7.  141 
  142 
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Discussion 143 
The key finding of this study is the increased risk of DM following TB; over a five-fold increased 144 
risk of DM in a multivariate analysis, possibly reducing to around a two-three fold increased 145 
risk after external control of confounding. As far as we are aware, no other cohort studies has 146 
been able to adequately quantify the risk of DM among people who have had TB; although 147 
many experts have speculated that this risk might be bi-directional(13, 19). Whilst studies in 148 
high TB incidence countries are ideally needed to confirm this risk and its population 149 
importance, they may be difficult to conduct in practice, due to the large sample size (and 150 
length of follow-up) required. Thus, other studies using big datasets, more routinely available 151 
in the developed world, should be analysed to confirm this association. 152 
Although data is limited it could be biologically plausible that the risk of developing DM is 153 
higher after TB disease. Some recent animal models of Mtb have seen unexpected 154 
development of DM (e.g. among guinea pigs), particularly those treated with anti-glycaemic 155 
therapy as host-directed therapy for TB(20). Studies have shown induced hyperglycaemia 156 
and/or impaired glucose tolerance occur during the early phases of active TB disease(21, 22), 157 
and these metabolic states themselves are linked with progression to overt DM amongst 20-158 
50% of individuals after three to five years(23). In a recent Indian cohort study, TB patients 159 
with newly diagnosed DM had markedly lower HbA1c values (although still abnormal) 160 
compared to those with known DM, suggesting that TB might, at least transiently, stimulate 161 
progression from intermediate hyperglycaemia to frank DM or identify those individuals who 162 
may be more prone to metabolic alterations or DM in the future(24). Thus, TB disease may 163 
identify individuals at higher risk of progression to DM, in much the same was as gestational 164 
DM identifies groups at high risk of progression to overt DM. Another possible mechanism by 165 
which TB may increase DM risk is through changes in body composition during and following 166 
the illness. TB patients frequently lose a substantial amount of weight before and in early 167 
stages of treatment; limited evidence from cohort studies suggests that weight re-gain during 168 
treatment could increase the proportion of body fat in recovered TB patients(25, 26); hence 169 
increasing their future risk of DM.  170 
This study found modest associations between DM (as exposure) and TB (as outcome) after 171 
controlling for key confounders(15). However, the novelty of this analysis is the large sample 172 
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size and hence power to show an increased risk of EPTB as well as PTB (of similar magnitude; 173 
1.4 to 1.5 fold increases). Some studies from LMIC have suggested that only PTB risk is 174 
increased among DM patients, which may be explained by a cell-mediated immune response 175 
in DM patients inhibiting dissemination outside the lung(27). In the UK, most TB is likely to be 176 
due to re-activation compared with LMIC, so it is possible that in the UK individuals may have 177 
seeds of Latent Mtb at extra-pulmonary sites that occurred prior to the onset of DM, and 178 
suggest that immune containment of Mtb is generally deficient among people with DM.  179 
The magnitude of the increased risk of TB in people with DM (about 1.3 fold increased risk 180 
over both sub-types) is lower than that first reported in systematic reviews(28, 29), but in line 181 
with more recent and larger studies, particularly those in developed countries including one 182 
recently published from the Clinical Practice Research Database (CPRD) in the UK(11, 30). The 183 
slightly weaker association in these recent studies may reflect a strong primary care health 184 
system with relatively good glycaemic control and management of co-morbidities among 185 
patients with DM(11). This hypothesis is supported by the stronger association (about a 2.5-186 
fold association) found in the early NHANES II study (1978-80), even after control for key 187 
confounders(7), and several recent studies suggesting stronger associations between DM and 188 
TB risk where glycaemic control is poor(31).  189 
Our finding of an increased DM risk after TB needs to be interpreted cautiously. Some studies 190 
have noted that the hyperglycaemia observed amongst populations of individuals with TB is 191 
transient, reversing after the early, acute phase of TB infection(22, 32), although others have 192 
suggested it is permanent(33). It could be that some of these observations of hyperglycaemia 193 
are due to short-term side effects of treatment with rifampicin and isoniazid(34), or, to stress 194 
hyperglycaemia rather than being signs of true metabolic dysfunction and DM. Our findings 195 
by TB sub-type also need to be carefully assessed as many patients did not have TB type 196 
classified; though most likely these are PTB cases.  197 
Diagnosis with T2DM is often delayed, even in developed countries with strong primary health 198 
care systems such as the UK(35). With the majority of DM cases in the UK being T2DM we 199 
therefore cannot be certain if the TB disease occurred prior to DM onset, even among those 200 
individuals without a previous diagnosis of DM. Longer follow-up time periods are ideally 201 
required to fully tease out whether TB disease is itself increasing the risk of DM or whether it 202 
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is a more a presenting feature of DM. However, T1DM is usually much more rapid in onset 203 
and should be quickly diagnosed in the UK(36), so possible reverse causality is less likely when 204 
T1DM is diagnosed after having TB disease. Given the lack of any screening programmes for 205 
TB and DM, the effect of misclassification may be non-differential; biasing estimates towards 206 
the null. However, even if uncertainties concerning the mechanism and direction of the 207 
association remain, our finding of an increased risk of DM among former TB patients could 208 
have important clinical and public health implications. Lifetime risk of developing DM is 209 
already very high in many TB endemic countries(2); assuming the increased risk among TB 210 
patients is real, it could turn out to be highly cost-effective to screen former TB patients at 211 
regular intervals for DM; thus reducing the risks of expensive complications and improving 212 
long-term health outcomes from DM. TB patients with DM also appear to be more infectious 213 
(having both a higher bacterial load, and remaining smear positive for longer) than patients 214 
without DM, and also experience more recurrent TB(3, 37). These factors also suggest TB 215 
patients at risk of, or already with, overt DM may be driving continued TB transmission 216 
disproportionate to their population size and may require different treatment guidelines(38). 217 
The key strengths of our analyses are the true cohort design and size of the database. The 218 
very large size, several orders of magnitude larger than most of studies on this topic, has 219 
allowed us to assess the associations with disease subgroups (PTB and EPTB) and also the risk 220 
of TB disease leading to future DM; topics barely covered (sub-types) or assessed at all (TB 221 
leading to DM) in previous analyses. Our study was based on routine health care records 222 
collated in primary care. DM is routinely managed in primary care, and the UK GP Quality and 223 
Outcomes Framework (implemented after 2004) incentivised GPs to diagnose and treat DM 224 
patients(39), thus DM status was highly likely being recorded accurately(40). Our dataset may 225 
slightly underestimate the true incidence of TB as care will mainly be instigated and 226 
completed by secondary providers. However, we believe that in most cases TB relevant 227 
information will be fed back to primary care, as TB is a serious, notifiable infection. Supporting 228 
this assumption is that the rates of TB identified in THIN were comparable to UK rates (TB 229 
incidence of 14.6 per 100,000 in 2009) meaning it is unlikely that misclassification is occurring 230 
to a great extent.  231 
Although we adjusted for key confounders (SES, age, sex, smoking status)(7, 11), our 232 
estimates could still be affected by residual confounding. We were unable to adjust directly 233 
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for other confounders that could be of interest (such as ethnicity or BMI) with this dataset. 234 
Our previous analyses using the NHANES dataset from the US did not find substantial 235 
attenuation of associations after adjusting for a more comprehensive range of potential 236 
confounders(7), and another recent analysis of data from primary care in the UK using the 237 
CPRD database also found no effect modification from ethnicity, age, or duration of DM(11). 238 
BMI is associated with the development of DM and TB; besides, TB patients also lose weight 239 
which is rapidly regained on treatment. Hence even single measurements of BMI may not be 240 
sufficient to adjust for potential confounding effects. More detailed analyses, potentially 241 
treating BMI as a time-varying exposure, are thus required, but are not currently available. 242 
We acknowledge that the potential for residual confounding by ethnicity is clearly important 243 
since DM risk is substantially increased in Black Afro-Caribbean and South Asian populations, 244 
compared with White British people, and the majority of TB cases reported in the UK also 245 
occur in these minority groups. For this reason we performed an external adjustment for 246 
ethnicity, which suggested that the true RR for DM among those with prior TB could be 247 
reduced from 5.65 to around 2.33-2.90, but still remained statistically significant and clinically 248 
important.  249 
Our analyses are the first globally to cautiously add epidemiological support to a hypothesis 250 
that the association between TB and DM could be bi-directional. This may have implications 251 
for future health care for people with a history of TB disease, who are not routinely assessed 252 
for DM or informed that they may be at higher risk of DM in the future. WHO guidelines 253 
recommend screening all TB patients for DM globally, but these are not yet routinely 254 
implemented; moreover, it is unknown what the long term health supports are needed for 255 
former TB patients subsequently developed hyperglycaemia. Whilst this may be of most 256 
importance for population health in high TB-DM burden countries, it is also important among 257 
ethnic minority groups in low burden countries such as the UK, who may be at higher risk of 258 
both TB and DM(41).  259 
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What is already known on this subject? 281 
It is known that having diabetes increases your chance of developing active TB. However, 282 
although plausible, it was not known if having TB increase your future risk of developing 283 
DM. 284 
What this study adds? 285 
This study shows that having had TB individuals are at an increased risk of developing DM. It 286 
is thus important to consider follow up, in particular screening, for such long term 287 
complications.  288 
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Figure 1 Flowchart of cohorts within study population 392 
 393 
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Table 1 Sex, age, SES and smoking distribution within all cohorts 
 
  DM Cohort  TB Cohort      
    TB  PTB  EPTB  
Variables  Number (%)  Number % Number % Number % 
 Total  224,508 100 5,470 100 1,589 100 1,006 100 
Sex 
  
Male 123,264 54.9 2,698 49.3 856 53.9 440 43.7 
Female 101,244 45.1 2,772 50.7 733 46.1 566 56.3 
Age Group 0-15 3,045 1.3 394 7.2 68 4.2 67 6.7 
16-30 8,696 3.9 1,035 19 236 14.9 174 17.4 
31-45 29,576 13.1 375 19.3 78 16.4 239 23.8 
46-60 63,977 28.5 1,109 20.3 328 20.7 211 21.1 
61-75 80,235 35.7 1,268 23.2 473 29.8 226 22.6 
76+ 38,979 17.4 584 10.7 219 13.8 85 8.5 
Townsend 
quintile 
1 45,608 20.3 774 14.1 210 13.2 152 15.1 
2 44,518 19.8 800 14.6 234 14.7 136 13.5 
3 45,121 20.1 1,017 18.6 280 17.6 216 21.5 
4 43,283 19.3 1,193 21.8 376 23.7 221 22.0 
5 32,502 14.5 1,252 22.9 364 22.9 212 21.1 
Smoker Yes 62,288 27.7 1,449 26.5 420 26.4 254 25.2 
Past 119,619 53.3 2,236 40.9 781 49.2 410 40.8 
No 42,601 19.0 1,785 32.6 388 24.4 342 34.0 
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Table 2 IRRs, 95%CI and P-values for the occurrence of DM amongst people with TB 
Exposure  Outcome  
Unadjusted IRR 
(95%CI) 
P-value 
Adjusted IRR 
(95%CI)1 
P-value 
TB DM 6.38 (5.69-7.16) <0.001 5.65 (5.19-6.16) <0.001 
PTB DM 8.03 (6.90-9.34) <0.001 5.74 (5.08-6.49) <0.001 
EPTB DM 5.42 (4.46-6.58) <0.001 4.66 (3.94-5.51) <0.001 
DM TB 1.62 (1.37-1.92) < 0.001 1.50 (1.27-1.76) <0.001 
DM PTB 1.74 (1.30-2.32)  <0.001 1.24 (0.93-1.64)  0.137 
DM EPTB 1.56 (1.09-2.24)  0.016 1.43 (0.99-2.07) 0.055 
1Adjusted for age, sex, region, Townsend score and smoking status  
 
 
 
